BPC+TB Blend

The BPC-157 + TB-500 Blend is a research-format combination of two structurally and mechanistically unrelated tissue-repair peptides: BPC-157 (Body Protection Compound-157, a 15-amino-acid peptide derived from a human gastric protein) and TB-500 (a synthetic peptide based on the actin-binding domain of thymosin β4). The two constituents have been investigated in independent research programs targeting overlapping injury and tissue-repair endpoints — angiogenesis, fibroblast and endothelial migration, tendon and ligament healing, cardiovascular repair — through different molecular mechanisms. The blend documents this complementary-mechanism rationale; it does not represent a single compound with its own characterized pharmacology.

There is no peer-reviewed clinical or preclinical literature on the BPC-157 + TB-500 combination as a fixed-ratio research product. The published research base consists of separate literatures on each constituent: predominantly rodent and in vitro studies for BPC-157 (the Sikiric laboratory in Croatia and collaborators), and a mix of rodent wound-healing and cardiac-repair studies plus the foundational pharmacology work for thymosin β4 and its actin-binding fragments (the Goldstein, Kleinman, Bock-Marquette, and Riley laboratories at NIH, Children’s Hospital of Philadelphia, UT Southwestern, and UCL). The combination rationale is mechanistic rather than empirical: BPC-157 mechanistic work has converged on the VEGFR2–Akt–eNOS angiogenic pathway and the FAK–paxillin fibroblast-migration pathway, while thymosin β4 / TB-500 mechanistic work has centered on G-actin sequestration, integrin-linked kinase (ILK) signaling, and epicardial progenitor mobilization. These are non-overlapping molecular pathways.

Neither BPC-157 nor TB-500 is approved by the FDA, EMA, or any other regulatory authority for any indication. BPC-157 was advanced into Phase 1 and Phase 2 clinical development by the Croatian pharmaceutical company Pliva (as the PL 14736 formulation) for inflammatory bowel disease research; Phase 1 safety data appeared in conference proceedings, but full Phase 2 efficacy results have not been published in the peer-reviewed literature. Thymosin β4 (the parent molecule of TB-500) has been investigated in clinical trials for ophthalmic, cardiac, and dermal repair under development codes including RGN-259 and RGN-352. Researchers should interpret the combination blend as a research-format product with no head-to-head combination data and should consult the constituent compound hubs for full mechanistic detail.

Important Note on the Evidence Base

Important note on the evidence base: No peer-reviewed clinical or preclinical study has compared the BPC-157 + TB-500 fixed-ratio combination against either constituent alone or against placebo, in any model. Claims that the combination produces additive or synergistic effects rest on mechanistic plausibility (the two constituents act through non-overlapping pathways) rather than on direct empirical comparison. The published research summarized below is the constituent-level literature; readers should interpret it accordingly and consult the individual compound hubs (BPC-157, TB-500) for full constituent-level depth.

Mechanism of Action

The proposed rationale for combining BPC-157 with TB-500 in a single research format rests on the observation that the two constituents act through molecularly distinct repair pathways. This section summarizes each constituent’s mechanism at the level needed to understand the combination rationale; full constituent-level mechanistic detail is available on the individual compound hubs.

BPC-157 — angiogenesis via VEGFR2 and fibroblast migration via FAK–paxillin. The most characterized BPC-157 mechanism is pro-angiogenic activity via upregulation of vascular endothelial growth factor receptor 2 (VEGFR2), with downstream activation of the protein kinase B (Akt) and endothelial nitric oxide synthase (eNOS) pathway, as reported by Hsieh and colleagues in a rat hindlimb ischemia model and complementary in vitro angiogenesis assays [1]. A separate line of BPC-157 mechanistic work has characterized concentration-dependent stimulation of tendon-fibroblast migration via focal adhesion kinase (FAK) and paxillin phosphorylation, with parallel improvements in tendon and ligament healing in rat surgical models [2]. BPC-157 also modulates the nitric oxide system and has been characterized as stable in human gastric juice without enzymatic degradation.

TB-500 / thymosin β4 — G-actin sequestration and cell migration. Thymosin β4 is a 43-amino-acid endogenous peptide first isolated from bovine thymus and characterized as the major G-actin-sequestering protein in eukaryotic cells. TB-500 is a synthetic peptide derived from the active actin-binding domain of thymosin β4. Goldstein, Hannappel, and Kleinman reviewed the foundational thymosin β4 biology in Trends in Molecular Medicine, characterizing the molecule as the major actin-sequestering molecule in eukaryotic cells with documented activity in dermal- and corneal-wound healing models [3]. The G-actin sequestration activity is the basis for the molecule’s effects on cell migration, since regulated release of G-actin into polymerized filaments is required for the cytoskeletal rearrangements that drive directed cell movement during wound repair.

TB-500 / thymosin β4 — wound healing and cardiac repair. Malinda and colleagues reported that topical or intraperitoneal thymosin β4 administration in a rat full-thickness wound model increased reepithelialization by 42% over saline controls at 4 days and by 61% at 7 days post-wounding, with increased collagen deposition and angiogenesis in the treated wounds [4]. A separate landmark study by Smart and colleagues, published in Nature, identified thymosin β4 as essential for coronary vessel development in mice and demonstrated that the peptide stimulates outgrowth from quiescent adult epicardial explants, restoring pluripotency and triggering differentiation of fibroblasts, smooth muscle cells, and endothelial cells [5]. The Smart 2007 finding repositioned thymosin β4 as a candidate for adult cardiac-repair research, and the peptide and its derivatives have since been investigated in clinical trials for myocardial infarction recovery.

Combination rationale. The mechanistic case for combining BPC-157 with TB-500 rests on the non-overlapping molecular profile of the two constituents. BPC-157 acts on the endothelial cell (via VEGFR2) and the tendon fibroblast (via FAK–paxillin) with concurrent NO-system modulation; TB-500 acts on the actin cytoskeleton (via G-actin sequestration) with downstream effects on cell migration and epicardial progenitor mobilization. The two mechanism classes operate on different molecular substrates and are not redundant. Whether this mechanistic non-overlap translates to additive or synergistic effects in any specific injury model has not been directly tested in the peer-reviewed literature. Researchers planning combination protocols should be explicit about this gap in the evidence base.

Available Forms

Omnix Peptides supplies the BPC-157 + TB-500 Blend in three research formats. Each lot is independently characterized by HPLC and LC–MS, with a batch-specific Certificate of Analysis available on each product page.

• BPC-157 + TB-500 Blend Vial — lyophilized powder for reconstitution. Available in 10 mg and 20 mg total-peptide strengths per vial. The vial is the canonical research format used in most of the published preclinical literature on both constituents.
• BPC-157 + TB-500 Blend Capsules — 1000 mcg total peptide per capsule, 60-count bottle. Oral format used in research models evaluating enteral delivery of the two constituents in a fixed ratio.
• BPC-157 + TB-500 Blend Liquid Spray — 60 mg total peptide per 30 mL bottle. Mucosal-administration format used in research models evaluating non-injectable delivery routes.

The blend is classified under the Recovery & Healing research category. For research framed around the constituents individually, see the BPC-157 and TB-500 compound hubs. For research framed around skin and dermal repair specifically — including a different combination format that adds GHK-Cu to BPC-157 and TB-500 — see the Glow Blend hub.

Amount in the Published Research Literature

The following administration ranges describe the protocols used in the peer-reviewed literature on the individual constituents. They are reported here for research-reference purposes only and do not constitute administration recommendations of any kind. No combination-specific amount protocols have been published in the peer-reviewed literature.

BPC-157 rodent injury and tissue-repair studies. The published Sikiric-laboratory rodent literature has typically administered BPC-157 in one of two amount ranges: a microgram-per-kilogram range (commonly 10 µg/kg) and a nanogram-per-kilogram range (commonly 10 ng/kg), with both reported to produce measurable effects in tendon, ligament, gastrointestinal, and cardiovascular injury models [2]. Administration routes have included intraperitoneal injection, intragastric (oral) gavage, oral administration in drinking water, and topical application. Full BPC-157 amount-protocol detail is available on the BPC-157 compound hub.

TB-500 / thymosin β4 rodent wound-healing protocols. The Malinda 1999 wound-healing study administered thymosin β4 topically (5 µg per wound in PBS) and intraperitoneally (150 µg per animal) in a rat full-thickness wound model, with reepithelialization assessed at 4 and 7 days post-wounding [4]. The Smart 2007 cardiac-repair study used intraperitoneal thymosin β4 administration at 150 µg per mouse with epicardial explant outgrowth and adult-mouse coronary vessel assessment [5]. Subsequent thymosin β4 clinical trials have used intravenous administration in the milligram range over short courses.

Combination protocols. The published research base does not contain peer-reviewed studies of fixed-ratio BPC-157 + TB-500 combination administration in any model. Researchers planning combination protocols are referred to the constituent literature on each compound and should treat any combination administration as exploratory in the absence of head-to-head data.

Researchers planning protocols are referred to the original primary literature cited in the References section for full methodological detail, including vehicle composition, injection volume, treatment-timing relative to injury, and outcome assessment timepoints.

Frequently Asked Questions

References

1. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y · PubMed: 27847966
2. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010 · PubMed: 21030672
3. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. doi:10.1016/j.molmed.2005.07.004 · PubMed: 16099219
4. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. doi:10.1046/j.1523-1747.1999.00708.x · PubMed: 10469335
5. Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182. doi:10.1038/nature05383 · PubMed: 17108969

For Research Use Only. The products described on this page are sold strictly for in vitro laboratory research and are not intended for human or animal consumption, diagnostic use, or therapeutic use. The published research summarized above is provided as scientific reference material. Nothing on this page constitutes medical advice, a therapeutic claim, or a recommendation for any use outside of a properly resourced and ethically reviewed research setting.